University of Tabriz Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Tabriz Iran (Islamic Republic of) (1947)

Organization Overview

First Clinical Trial
2005
NCT00456404
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Cardiovascular research center, Tabriz university of medical sciences | Drug Applied Research Center, Tabriz Univ Med Sci | Islamic Azad University of Tabriz | Research Center for Gastroenterology and Hepatology, Tabriz University of Medical Sciences, Tabriz | Tabriz University | Tabriz University of Medical Sciences, Tabriz, Iran | Tabriz Univ Med Sci | Urology department ofTabriz University of Medical Sciences | Women Reproductive Health Research Center,Tabriz University of medical Sciences

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Central Serous Chorioretinopathy (Phase 2)

Dental Plaque (Phase 2)

Diabetic Retinopathy (Phase 4)

Gingivitis (Phase 2)

Heart Failure (Phase 2)

Hemophilia A (Phase 4)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis C (Phase 4)

Hyperlipidemias (Phase 3)

Hyperlipoproteinemias (Phase 3)

Infertility (Phase 3)

Infertility, Male (Phase 3)

Inflammation (Phase 2)

Intervertebral Disc Displacement (Phase 2)

Osteoarthritis (Phase 2)

Pain, Postoperative (Phase 2)

Retinal Diseases (Phase 4)

Schizophrenia (Phase 1)

Spondylitis (Phase 2)

Spondylitis, Ankylosing (Phase 2)

Thalassemia (Phase 4)

Urinary Bladder, Neurogenic (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 17
  • # of Trial APIs: 30